Photodynamic immunotherapy using ADU-S100-modified nanoparticles to treat triple-negative breast cancer-Reference-Cited by-全球学者库

Photodynamic immunotherapy using ADU-S100-modified nanoparticles to treat triple-negative breast cancer

Published:2023-04 Issue:9 Volume:18 Page:755-767
ISSN:1743-5889
Container-title:Nanomedicine
language:en
Short-container-title:Nanomedicine

Author:

Ge Tong¹^ORCID,Ge Wenshu²,Zhang Ludan²^ORCID,Yu Guohui¹^ORCID,Li Yi¹^ORCID,Sun Lisha²,Dong Fan²,Yao Zhi¹,Shi Lei¹,Wang Yuguang²

Affiliation:

1. Department of Immunology, Key Laboratory of Immune Microenvironment & Disease of the Educational Ministry of China, Tianjin Key Laboratory of Cellular & Molecular Immunology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, 300070, China

2. Center of Digital Dentistry/Department of Prosthodontics, National Center of Stomatology, National Clinical Research Center for Oral Diseases, National Engineering Laboratory for Digital & Material Technology of Stomatology, Beijing Key Laboratory of Digital Stomatology, NHC Research Center of Engineering & Technology for Computerized Dentistry, Department of General Dentistry II, Central Laboratory, Peking University School & Hospital of Stomatology, Beijing, 100081, China

Abstract

Aim: STING agonists in immunotherapy show great promise and are currently in clinical trials. Combinations of STING agonists with other therapies remain underexplored. This study aimed to combine STING agonist-mediated immunotherapy with photodynamic therapy to treat breast cancer. Methods: STING agonist (ADU-S100)-functionalized porphyrin-based nanoparticles (NP-AS) were prepared and their antitumor properties in terms of cell apoptosis/necrosis and immune activation in triple-negative breast cancer were evaluated. Results: NP-AS induced tumor cell apoptosis/necrosis, activated the innate immune response and exhibited useful antitumor effects. Conclusion: NP-AS effectively treated breast cancer.

Funder

National Natural Science Foundation of China

Publisher

Future Medicine Ltd

Subject

Development,General Materials Science,Biomedical Engineering,Medicine (miscellaneous),Bioengineering

Link

https://www.futuremedicine.com/doi/pdf/10.2217/nnm-2022-0299

Reference43 articles.

1. An overview of triple-negative breast cancer

2. Tumor cell lysate-loaded immunostimulatory spherical nucleic acids as therapeutics for triple-negative breast cancer

3. Cancer statistics, 2015

4. Clinical Applications for Targeted Therapy in Bladder Cancer

5. Amplifying STING activation by cyclic dinucleotide–manganese particles for local and systemic cancer metalloimmunotherapy